特写特讯！沪深股市：A股市场三大指数震荡收涨，北交所指数涨逾2%

沪深股市：A股市场三大指数震荡收涨，北交所指数涨逾2%

2024年6月13日讯，今日A股市场三大指数震荡收涨，沪指涨0.57%，深成指涨0.72%，创业板指涨0.93%。北交所指数涨幅较大，涨逾2%。

市场概况

• 今日A股市场成交量有所放大，沪深两市全天成交额超1.1万亿元。
• 盘面热点主要集中在医药卫生、电子信息、军工等板块。
• 北交所市场今日表现活跃，成交额超100亿元，多只个股涨停。

个股表现

• 医药板块中，以岭药业、迈瑞医疗、爱尔眼科等个股涨幅较大。
• 电子信息板块中，歌尔股份、立讯精密、韦尔股份等个股涨幅居前。
• 军工板块中，中国兵器、航空工业、航天科技等个股表现强劲。

北交所市场

• 北交所市场今日成交额超100亿元，多只个股涨停。
• 北交所板块中，医药卫生、电子信息、新材料等板块表现活跃。

市场人士观点

• 市场人士认为，今日A股市场三大指数震荡收涨，主要得益于近期市场利好政策频出，市场信心有所增强。
• 此外，北交所市场今日表现活跃，也为市场增添了一些人气。
• 展望后市，市场人士认为，A股市场仍将保持震荡上行态势，投资者可关注医药卫生、电子信息、军工等板块的投资机会。

（来源：新浪财经）

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.